NovoCure Ltd
NVCR
Company Profile
Business description
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Contact
Grenville Street
No. 4 The Forum, Second Floor
St. HelierJE2 4UF
JEYT: +44 1534756700
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
1,488
Stocks News & Analysis
stocks
Our three most overvalued ASX shares
These three companies are trading at a significant premium to our fair value.
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,126.90 | 2.50 | -0.03% |
| CAC 40 | 7,734.84 | 35.92 | 0.47% |
| DAX 40 | 23,807.13 | 210.15 | 0.89% |
| Dow JONES (US) | 45,367.31 | 253.98 | -0.56% |
| FTSE 100 | 9,221.44 | 13.23 | 0.14% |
| HKSE | 25,633.91 | 215.93 | 0.85% |
| NASDAQ | 21,811.37 | 103.67 | 0.48% |
| Nikkei 225 | 43,643.81 | 625.06 | 1.45% |
| NZX 50 Index | 13,281.14 | 57.61 | 0.44% |
| S&P 500 | 6,491.52 | 10.02 | 0.15% |
| S&P/ASX 200 | 8,849.60 | 5.60 | -0.06% |
| SSE Composite Index | 3,826.84 | 14.33 | 0.38% |